Chest
Clinical Investigations: DyspneaValidation of a New Dyspnea Measure: The UCSD Shortness of Breath Questionnaire
Section snippets
Subjects
The 54 subjects in this study were a convenience sample of patients evaluated at the University of California, San Diego Pulmonary Rehabilitation Program. Subjects ranged in age from 12 to 82 years; 41% were female (Table 1). Diagnostic breakdown was as follows: COPD (n=28), cystic fibrosis (CF) (n=9), and postlung transplant (n=17). Three patients with restrictive parenchymal disease and two patients with pulmonary vascular disease were excluded due to small sample size. Of the postlung
Results
Subject characteristics are shown in Table 1. The 28 subjects with COPD were older and had higher scores on the CESD, SOBQ, and Borg ratings of PB after the 6MW, with lower QWB scores. These were associated with lower 6MW distances, FEV1, Dco, MIP, and MEP. Mean scores on the old and new versions of the SOBQ were similar for each group, with slightly higher mean values on the new version.
An internal consistency criterion of 0.70 was chosen as good evidence for reliability.18 The SOBQ
Discussion
The results of this study and our previous experience4 indicate that the UCSD SOBQ is a reliable and valid instrument that can be used to assess dyspnea associated with ADLs in patients with moderate-to-severe chronic lung disease. Dyspnea is a primary symptom and an important outcome measure in evaluating patients with chronic lung diseases.19, 20 The choice of a dyspnea measure depends not only on the purpose of the application, but also on the reliability and validity of the measure.
We have
Appendix—UCSD SOBQ
UCSD Medical Center Pulmonary Rehabilitation Program Shortness-of-Breath Questionnaire ©1995 The Regents of the University of California
Instructions: For each activity listed below, please rate your breathlessness on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity. If the activity is one which you do not perform, please give your best estimate of breathlessness. Your responses should be for an “average” day during
References (28)
- et al.
Symptoms and experiences in chronic bronchitis and emphysema
Chest
(1983) - et al.
How should we measure function in patients with chronic heart and lung disease?
J Chronic Dis
(1985) - et al.
Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease
J Chronic Dis
(1984) - et al.
The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes
Chest
(1984) - et al.
The relationship between pulmonary function and dyspnea in obstructive lung disease
Chest
(1989) - et al.
Spirometry and dyspnea in patients with COPD: when small differences mean little
Chest
(1996) - et al.
Breathlessness in patients with severe chronic airflow limitation: physiologic correlations
Chest
(1992) - et al.
Measurement of dyspnea in chronic obstructive pulmonary disease
Qual Life Res
(1993) - et al.
Degree of objectively measured impairment and perceived shortness of breath with activities of daily living in patients with chronic obstructive pulmonary disease
Can J Rehab
(1987) - et al.
Reliability and validity of dyspnea measures in patients with obstructive lung disease
Int J Behav Med
(1995)
ATS statement-Snowbird work-shop on standardization of spirometry
Am Rev Respir Dis
Standardization of spirometry: a summary of recommendations from the American Thoracic Society
Ann Intern Med
Pulmonary function testing, guidelines and controversies: equipment, methods, and normal values
Assessment of respiratory function in chronic obstructive airway disease
Thorax
Cited by (343)
Expansion of distinct peripheral blood myeloid cell subpopulations in patients with rheumatoid arthritis-associated interstitial lung disease
2024, International ImmunopharmacologyPredictors of chronic thromboembolic pulmonary hypertension in patients with submassive pulmonary embolism treated with catheter-directed thrombolysis versus anticoagulation alone: A secondary analysis of the SUNSET sPE trial
2023, Journal of Vascular Surgery: Venous and Lymphatic DisordersIdiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
2023, Disease-a-Month
Presented in part at the annual meeting of the American Association of Cardiovascular and Pulmonary Rehabilitation, September 1994, Portland, Ore.
Supported by grants 2RT0268 from the University of California Tobacco Related Disease Research Program; HL34732 from the National Heart, Lung, and Blood Institute (Dr. Kaplan); and by Award No. HL02215 of the National Institutes of Health NHLBI Preventive Pulmonary Academic Award (Dr. Ries).
- †
Currently at the Oregon Research Institute, Eugene.